Cinqair (reslizumab); Teva Pharmaceuticals; For the treatment of severe
asthma, Approved March 2016
Nucala (mepolizumab); GlaxoSmithKline; For the treatment of severe asthma with an eosinophilic phenotype, Approved November 2015 Arnuity Ellipta (fluticasone furoate inhalation powder); GlaxoSmithKline; For the treatment of asthma, Approved August 2014